Furthermore, analysis of the pathways specifically de-regulated in cancer, have led to develop specific tumor inhibitors, as the farnesyltransferase inhibitor [5], the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab [6], or the proteasome inhibitor bortezomib [7]. The gene discussed is VEGFA; the disease is cancer.